Patents by Inventor Albert Collinson

Albert Collinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200289457
    Abstract: Provided herein are methods of managing feline diabetes, said methods include administering to a feline in need thereof a total daily dosage of about 5 to 50 mg of Compound 1, having the formula: or a pharmaceutically acceptable form thereof. Also provided herein are methods of managing feline diabetes by administering to a feline in need thereof an effective amount of a SGLT inhibitor, wherein said effective amount is no more than 10 to 30% of the dose required to produce an elevated frequency of diarrhea or loose stool in a healthy feline.
    Type: Application
    Filed: March 13, 2020
    Publication date: September 17, 2020
    Inventors: Michael Hadd, Albert Collinson, Brian Seed
  • Publication number: 20160251400
    Abstract: Disclosed are methods for identifying high affinity adaptor molecules that bind to both a circulating antibody and a target molecule and redirect the specificity of the circulating antibody to the target molecule. Exemplary high affinity adaptor molecules are also provided.
    Type: Application
    Filed: February 2, 2016
    Publication date: September 1, 2016
    Inventors: Albert Collinson, Peter Wagner, Matti Sallberg, Anders Vahlne, Gregor Schurmann, Robert Kamen
  • Patent number: 9284548
    Abstract: Disclosed are methods for identifying high affinity adaptor molecules that bind to both a circulating antibody and a target molecule and redirect the specificity of the circulating antibody to the target molecule. Exemplary high affinity adaptor molecules are also provided.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: March 15, 2016
    Assignee: Tripep AB
    Inventors: Albert Collinson, Peter Wagner, Matti Sällberg, Anders Vahlne, Gregor Schürmann, Robert Kamen
  • Publication number: 20150175694
    Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1? and IL-1? and neutralize IL-1? and IL-1? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1? and IL-1?) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1? and/or IL-1? activity is detrimental.
    Type: Application
    Filed: March 5, 2015
    Publication date: June 25, 2015
    Applicant: ABBVIE INC.
    Inventors: Albert COLLINSON, George Avgerinos, Richard DIXON, Tariq GHAYUR, Zehra KAYMAKCALAN
  • Publication number: 20140378666
    Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1? and IL-1? and neutralize IL-1? and IL-1? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1? and IL-1?) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1? and/or IL-1? activity is detrimental.
    Type: Application
    Filed: August 26, 2014
    Publication date: December 25, 2014
    Applicant: ABBVIE INC.
    Inventors: Albert COLLINSON, George Avgerinos, Richard DIXON, Tariq GHAYUR, Zehra KAYMAKCALAN
  • Publication number: 20140155579
    Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1? and IL-1? and neutralize IL-1? and IL-1? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1? and IL-?) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1? and/or IL-1? activity is detrimental.
    Type: Application
    Filed: May 23, 2013
    Publication date: June 5, 2014
    Applicant: AbbVie Inc.
    Inventors: Albert Collinson, George Avgerinos, Richard Dixon, Tariq Ghayur, Zehra Kaymakcalan
  • Patent number: 8475766
    Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1? and IL-1? and neutralize IL-1? and IL-1? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1? and IL-1?) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1? and/or IL-1? activity is detrimental.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: July 2, 2013
    Assignee: AbbVie Inc.
    Inventors: Albert Collinson, George Avgerinos, Richard Dixon, Tariq Ghayur, Zehra Kaymakcalan
  • Publication number: 20120271033
    Abstract: Disclosed are methods for identifying high affinity adaptor molecules that bind to both a circulating antibody and a target molecule and redirect the specificity of the circulating antibody to the target molecule. Exemplary high affinity adaptor molecules are also provided.
    Type: Application
    Filed: October 5, 2010
    Publication date: October 25, 2012
    Applicant: OPSONIC THERAPEUTICS INC.
    Inventors: Albert Collinson, Peter Wagner, Matti Sällberg, Anders Vahlne, Gregor Schürmann, Robert Kamen
  • Publication number: 20090232736
    Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1? and IL-1? and neutralize IL-1? and IL-1? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1? and IL-1?) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1? and/or IL-1? activity is detrimental.
    Type: Application
    Filed: December 11, 2008
    Publication date: September 17, 2009
    Inventors: Albert Collinson, George Avgerinos, Richard Dixon, Tariq Ghayur, Zehra Kaymakcalan
  • Patent number: 7491516
    Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1? and IL-1? and neutralize IL-1? and IL-1? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1? and IL-1? ) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1? and/or IL-1? activity is detrimental.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: February 17, 2009
    Assignee: Abbott Laboratories
    Inventors: Albert Collinson, George Avgerinos, Richard Dixon, Tariq Ghayur, Zehra Kaymakcalan
  • Publication number: 20070249577
    Abstract: The present invention relates to methods for reducing the risk of infection due to surgical or invasive medical procedures. The present invention also relates to methods for preventing infection due to surgical or invasive medical procedures.
    Type: Application
    Filed: April 4, 2007
    Publication date: October 25, 2007
    Inventors: Scott Hopkins, Robert Kessler, Albert Collinson, Joyce Sutcliffe
  • Publication number: 20070238719
    Abstract: The present invention relates to methods for reducing the risk of infection due to surgical or invasive medical procedures. The present invention also relates to methods for preventing infection due to surgical or invasive medical procedures.
    Type: Application
    Filed: May 10, 2006
    Publication date: October 11, 2007
    Inventors: Scott Hopkins, Robert Kessler, Albert Collinson, Joyce Sutcliffe
  • Publication number: 20030040083
    Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1&agr; and IL-1&bgr; and neutralize IL-1&agr; and IL-1&bgr; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1&agr; and IL-1&bgr; ) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1&agr; and/or IL-1&bgr; activity is detrimental.
    Type: Application
    Filed: June 28, 2001
    Publication date: February 27, 2003
    Inventors: Albert Collinson, George Avgerinos, Richard Dixon, Tariq Ghayur, Zehra Kaymakcalan